Jorge Martinez
Cardiovascular Disease · Syracuse, NYNPI 1902892714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 92 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$229
- Johnson & Johnson$185
- Novartis$154
- Sanofi-aventis U.S. LLC$150
- Amarin Pharma, Inc.$117
- Kowa Pharmaceuticals America, Inc.$97
- plus $481 from 13 others
What the payments were for
- Food & beverage$1,413100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $229 |
| Johnson & Johnson | 13 | $185 |
| Novartis | 10 | $154 |
| Sanofi-aventis U.S. LLC | 11 | $150 |
| Amarin Pharma, Inc. | 7 | $117 |
| Kowa Pharmaceuticals America, Inc. | 5 | $97 |
| Boehringer Ingelheim | 5 | $96 |
| Gilead | 4 | $60 |
| Edwards Lifesciences | 3 | $54 |
| Vifor Pharma, Inc. | 2 | $44 |
| AstraZeneca | 3 | $41 |
| Akcea Therapeutics, Inc. | 2 | $35 |
| Bayer | 2 | $33 |
| Pfizer | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Novo Nordisk | 1 | $20 |
| Abiomed | 1 | $18 |
| Grifols USA, LLC | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
How this compares
$1,413 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Syracuse
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.